Literature DB >> 19568285

Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin.

Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Srini V Kaveri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19568285     DOI： 10.1038/nrd2358-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  16 in total

1.  Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years.

Authors:  J Haas; M Maas-Enriquez; H-P Hartung
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

Review 2.  Intravenous immunoglobulin in MS: promise or failure?

Authors:  Franz Fazekas; Siegrid Strasser-Fuchs; Otto R Hommes
Journal:  J Neurol Sci       Date:  2007-04-20       Impact factor: 3.181

Review 3.  Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Nat Clin Pract Rheumatol       Date:  2007-05

4.  Shortage of human intravenous immunoglobulin--reasons and possible solutions.

Authors:  Jagadeesh Bayry; Michel D Kazatchkine; Srini V Kaveri
Journal:  Nat Clin Pract Neurol       Date:  2007-03

5.  How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?

Authors:  Jeffrey A Cohen
Journal:  Nat Clin Pract Neurol       Date:  2008-10-14

Review 6.  Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Authors:  Rocio S Lopez-Diego; Howard L Weiner
Journal:  Nat Rev Drug Discov       Date:  2008-11       Impact factor: 84.694

7.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.

Authors:  P S Sorensen; B Wanscher; C V Jensen; K Schreiber; M Blinkenberg; M Ravnborg; H Kirsmeier; V A Larsen; M L Lee
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

8.  Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.

Authors:  Anat Achiron; Irena Kishner; Ida Sarova-Pinhas; Havi Raz; Meir Faibel; Yael Stern; Mor Lavie; M Gurevich; Mark Dolev; David Magalashvili; Yoram Barak
Journal:  Arch Neurol       Date:  2004-10

9.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

10.  Rituximab and intravenous immune globulin for desensitization during renal transplantation.

Authors:  Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245
View more
  1 in total

Review 1.  Role of pathogens in multiple sclerosis.

Authors:  Jane E Libbey; Matthew F Cusick; Robert S Fujinami
Journal:  Int Rev Immunol       Date:  2013-11-22       Impact factor: 5.311
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.